Side-by-side · Research reference

AdipotidevsChonluten

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BAnimal-MechanisticHUMAN-REVIEWED8/38 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

01Mechanism of Action

Parameter

Adipotide

Chonluten

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Bronchial epithelial cells and respiratory mucosa tissue complexes

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

—

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

Chonluten

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

Frequency

Not specified in available data

Once or twice daily

Evidence basis

Preclinical animal models only

In vitro mechanistic

Human data

None — no clinical trials reported

—

Typical protocol dose

—

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

Duration

—

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

Clinical validation

—

None (PubMed indexed)

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Chonluten

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

Chonluten

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Documented adverse events

—

No published safety data in PubMed-indexed literature

Theoretical risks

—

Peptide hypersensitivity, GI intolerance (uncharacterized)

Drug interactions

—

Unknown — no pharmacokinetic studies available

Pregnancy / lactation

—

No data — avoid

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Chonluten

·Known hypersensitivity to peptide components

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

05Administration Protocol

Parameter

Adipotide

Chonluten

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

5. Cycle protocol

—

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.